<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>329</serviceExecutionTime><Drug id="86216"><DrugName>bevacizumab follow-on biologic, AXXO</DrugName><DrugNamesKey><Name id="42758588">bevacizumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>bevacizumab</Value><Types><Type>INN</Type></Types></Name><Name><Value>bevacizumab follow-on biologic, AXXO</Value></Name></DrugSynonyms><CompanyOriginator id="1085691">AXXO Im und Export GmbH</CompanyOriginator><CompaniesPrimary><Company id="1085691">AXXO Im und Export GmbH</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1085691" type="Company"><TargetEntity id="5040054571" type="organizationId">Axxo GmbH</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3672" type="ciIndication"><TargetEntity id="10055114" type="MEDDRA"></TargetEntity><TargetEntity id="2341" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Metastatic colon cancer - Russian Federation - Jul-2013</FirstLaunched><FirstLaunched>Non-small-cell lung cancer - Russian Federation - Jul-2013</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="3672">Metastatic colon cancer</Indication></IndicationsPrimary><ActionsPrimary><Action id="12521">VEGF ligand inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="55685">Anticancer monoclonal antibody</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="740">Infusion</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="961">Follow on biological product</Technology></Technologies><LastModificationDate>2013-07-09T12:21:33.000Z</LastModificationDate><ChangeDateLast>2013-07-11T00:00:00.000Z</ChangeDateLast><AddedDate>2013-07-09T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1085691"&gt;AXXO&lt;/ulink&gt; has developed and launched a follow-on biologic version of the anti-VEGF humanized mAb  &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; for the treatment of metastatic colorectal cancer and non-small cell lung cancer. By July 2013, the product had been launched, presumably in Russia [&lt;ulink linkType="Reference" linkID="1446968"&gt;1446968&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1085691">AXXO Im und Export GmbH</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3672">Metastatic colon cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-02T00:00:00.000Z</StatusDate><Source id="1446968" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085691">AXXO Im und Export GmbH</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-02T00:00:00.000Z</StatusDate><Source id="1446968" type="CORPORATE"></Source></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-03154"><Name>VEGF ligand</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1446968" linkType="reference" linkID="1446968"&gt;1446968&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>